"For years, debate centered on 'spread pricing', the difference between what PBMs bill health plans and what they pay pharmacies. But this year, that narrow focus has widened. Regulators and lawmakers are looking deeper into how PBMs' ownership structures, reimbursement methods, and internal routing decisions shape the true cost of prescription drugs."  MORE >>